SC 13G: BRISTOL MYERS SQUIBB CO
Ticker: CELG-RI · Form: SC 13G · Filed: Oct 4, 2024 · CIK: 14272
| Field | Detail |
|---|---|
| Company | Bristol Myers Squibb Co (CELG-RI) |
| Form Type | SC 13G |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by BRISTOL MYERS SQUIBB CO.
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Bristol Myers Squibb Co (ticker: CELG-RI) to the SEC on Oct 4, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securitie).
How long is this filing?
Bristol Myers Squibb Co's SC 13G filing is 3 pages with approximately 880 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 880 words · 4 min read · ~3 pages · Grade level 9.2 · Accepted 2024-10-04 16:20:38
Key Financial Figures
- $0.00001 — ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securitie
Filing Documents
- ef20036681_sc13g.htm (SC 13G) — 49KB
- 0001140361-24-042895.txt ( ) — 51KB
(a)
Item 1(a). Name of Issuer: Prime Medicine, Inc. (the "Issuer")
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 60 First Street, Cambridge, MA 02141
(a)
Item 2(a). Names of Person Filing: This statement is filed by the Bristol-Myers Squibb Company, referred to herein as the "Reporting Person."
(b)
Item 2(b). Address of the Principal Business Office or if None, Residence: Route 206 & Province Line Road, Princeton, NJ 08543
(c)
Item 2(c). Citizenship: See response to Item 4 on the cover page.
(d)
Item 2(d). Title of Class of Securities: Common Stock, par value $0.00001 per share
(e)
Item 2(e). CUSIP Number: 74168J101 Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: Not Applicable Item 4. (a) Amount beneficially owned: See response to Item 9 on the cover page. (b) Percent of class: See response to Item 11 on the cover page. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote See response to Item 5 on the cover page. (ii) Shared power to vote or to direct the vote See response to Item 6 on the cover page. (iii) Sole power to dispose or to direct the disposition of See response to Item 7 on the cover page. (iv) Shared power to dispose or to direct the disposition of See response to Item 8 on the cover page. The filing of this Statement shall not be construed as an admission that the Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement. On September 28, 2024, the Issuer entered into a Securities Purchase Agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell 11,006,163 shares of Common Stock to the Reporting Person (the "Sale"). The Sale closed on September 30, 2024. Item 5. Not Applicable. Item 6. Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not Applicable. Item 8. Identification and Classification of Members of the Group. Not Applicable. Item 9. Notice of Dissolution of Group. Not Applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect